Nick George has more than 30 years of experience developing and evaluating biologics-based patent portfolios. He has devised worldwide patent prosecution strategies involving such diverse technologies as therapeutic antibodies, antibody drug conjugates, cellular therapeutics (including stem cell, natural killer cell, macrophage, regulatory cell, chimeric antigen receptor, and induced pluripotent stem cell [iPSC] therapeutics), gene therapies, oncolytic viruses, gene editing, antisense and mRNA therapeutics, peptide therapeutics, diagnostics, and enzyme replacements, among others.
Nick has developed patent strategies for such marketed products as Fuzeon®, Kynamro®, Fabrazyme®, Syvek®, and Talymed® and for clinical and pre-clinical candidates of such companies as BioMarin Pharmaceutical, BMS/Celgene, Celldex Therapeutics, Coya Therapeutics, and Turnstone Biologics. He also has developed patent strategies for such diagnostic products as Phenosense™, GeneSeq™, Replication Capacity™, and the companion diagnostic, Trofile™.
Nick also routinely provides advice on freedom-to-operate, noninfringement, invalidity, and patentability matters and conducts due diligence on behalf of investment firms and life sciences companies.
Nick holds a Ph.D. in genetics from the University of California, Berkeley (1990). Following a postdoctoral fellowship at Columbia University, he joined the legal intern program at his previous firm, during which time he also attended the evening program of Fordham University School of Law.
- October 19, 2022
East-West Biopharma Summit Road Trip, New York City, October 19, 2022
- Fordham University (J.D. 1997); Columbia University (Postdoctoral Fellow, 1990-1992); University of California, Berkeley (Ph.D. in Genetics 1990); University of Dallas (B.S. in Biology cum laude 1984)
- New York and registered to practice before the United States Patent and Trademark Office